Business Context and Reporting Period
The supplied filing is MultiPlan Corporation’s Form 10-K for the fiscal year ended December 31, 2022, filed March 1, 2023. The request metadata references Claritev Corp and “2022 Q4,” but the filing identifies the registrant as MultiPlan Corporation and reports full-year results, not a standalone fourth quarter.
MultiPlan provides data analytics, healthcare cost-management, provider-network, payment-integrity and revenue-integrity services to healthcare payors. The company processed $155.2 billion of medical charges and identified approximately $22.3 billion of potential savings in 2022. It had more than 1.3 million contracted providers, over 700 payor customers and approximately 2,500 employees.
Key Financial Metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $1,079.7 million | $1,117.6 million | Down 3.4% |
| Operating income (loss) | $(362.7) million | $386.1 million | Declined $748.9 million |
| Net income (loss) | $(572.9) million | $102.1 million | Declined $675.0 million |
| Basic EPS | $(0.90) | $0.16 | Declined from profit to loss |
| Adjusted EBITDA | $768.7 million | $838.3 million | Down 8.3% |
| Cash flow from operations | $372.4 million | $404.7 million | Down 8.0% |
| Capital expenditures and capitalized software | $89.7 million | $84.6 million | Up $5.1 million |
| Cash, cash equivalents and restricted cash | $340.6 million | $188.4 million | Up $152.2 million |
Revenue mix was approximately 92% commercial health plans and 8% payment and revenue integrity, property and casualty and other services. Approximately 92.2% of revenue was generated under percentage-of-savings arrangements, with 7.2% from per-employee-per-month arrangements.
Reported operating margin was approximately (33.6%) and net loss margin was approximately (53.1%). The results included $662.2 million of impairment charges, consisting of $657.9 million for goodwill and $4.3 million for indefinite-lived trade names. Excluding the impairment, adjusted EBITDA was $768.7 million, although this non-GAAP measure also excludes interest, amortization, stock compensation, transaction-related costs and other items.
Debt, Liquidity and Capital Resources
- Total debt before discounts and issuance costs was $4.82 billion at December 31, 2022; net long-term debt was $4.74 billion.
- Debt consisted primarily of a $1.31 billion Term Loan B, $1.16 billion of 5.750% senior notes, $1.05 billion of 5.50% senior secured notes and $1.30 billion of 6.00% cash/7.00% PIK convertible notes due 2027.
- The Term Loan B interest rate was 8.98% at year-end, and total debt had an annualized weighted-average cash interest rate of 6.67%, compared with 4.64% in 2021.
- The revolving credit facility had $448.2 million of available capacity after $1.8 million of letters of credit. The facility matures in August 2026; Term Loan B and the senior notes generally mature in 2027 or 2028.
- The company repurchased and cancelled $136.2 million principal amount of 5.750% notes during November and December 2022, recognizing a $34.6 million gain on extinguishment.
- Management stated that available cash, operating cash flow and revolver capacity should provide sufficient liquidity for the next twelve months and the long term, but cautioned that future liquidity depends on operating performance and capital-market access.
- The company was in compliance with its debt covenants at December 31, 2022. Consolidated first-lien debt to consolidated EBITDA was 2.64 times.
Material Changes Versus the Prior Comparable Period
- Revenue decreased 3.4%, driven primarily by an 11.9% decline in Network-Based Services and a 7.0% decline in Payment and Revenue Integrity Services. Analytics-Based Services revenue increased 0.6%.
- Claims volumes declined, partly because healthcare utilization and elective procedures remained below pre-pandemic levels. Average charge per claim increased.
- Costs of services increased 16.4% to $204.1 million, primarily from higher personnel, compensation, access and bill-review costs.
- General and administrative expenses increased 10.4% to $166.8 million, primarily because of transaction-related legal and settlement costs.
- Interest expense increased 13.4% to $303.4 million because of higher variable interest rates and the impact of the 2021 refinancing.
- Goodwill and intangible-asset impairment charges of $662.2 million were recorded in 2022 after a significant decline in market capitalization and higher discount rates.
- Operating cash flow remained positive but decreased 8.0%; cash used in investing activities declined to $104.4 million from $228.4 million because 2021 included the $149.7 million DHP acquisition.
Outlook, Commentary, Risks and Unusual Items
The filing does not provide formal revenue, earnings or cash-flow guidance. Management’s strategy is to improve existing services through technology and data investments, expand newer offerings such as value-driven health plans and No Surprises Act services, cross-sell across its customer base and pursue adjacent markets and acquisitions.
- COVID-19 and reduced healthcare utilization continued to negatively affect claims volumes and revenue, although the impact was less severe than in 2020 and 2021.
- The No Surprises Act and related rules create compliance and reimbursement uncertainty. Ongoing litigation and regulatory changes could alter the independent dispute-resolution process and the use of the qualifying payment amount.
- Customer concentration is significant: three customers accounted for approximately 32%, 20% and 10% of 2022 revenue.
- Variable-rate debt exposes the company to higher interest expense. A 100-basis-point change in Term Loan B rates would affect annual interest expense by approximately $13.1 million. The transition away from LIBOR may also increase borrowing costs.
- Goodwill and intangible assets totaled approximately $6.65 billion at year-end, including $3.71 billion of goodwill. Additional impairment charges remain possible if operating performance, forecasts, margins, market capitalization or discount rates deteriorate.
- The company accrued $24.3 million for a Delaware stockholder litigation settlement at year-end. The company and its insurers agreed to pay $33.75 million; the Court of Chancery approved the settlement on February 28, 2023, subject to finalization.
- Cybersecurity, privacy, HIPAA, healthcare regulation, litigation, provider-network retention, pricing pressure and customer attrition remain material risks.
- PricewaterhouseCoopers issued an unqualified opinion on the financial statements and internal control over financial reporting. Management and the auditor concluded that internal controls were effective as of December 31, 2022.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for MultiPlan Corporation, not Claritev Corp, and covers the full fiscal year ended December 31, 2022.
- Reconcile the company’s substantial debt burden, maturity schedule, variable-rate exposure and cash interest requirements against operating cash flow.
- Assess whether the 2022 revenue decline and lower claims volumes are temporary or reflect structural pressure on network-based services.
- Review the goodwill impairment assumptions and sensitivity to revenue growth, margins, discount rates and market capitalization.
- Evaluate customer concentration and contract-renewal risk, particularly for the three customers representing approximately 62% of revenue.
- Track the final resolution and cash impact of the Delaware stockholder litigation settlement.
- Consider dilution from the $1.30 billion convertible PIK notes, warrants, unvested founder shares and equity awards.
- Review the company’s non-GAAP adjustments, especially the unusually large impairment add-back in 2022, when assessing sustainable profitability.
- Monitor No Surprises Act litigation and regulatory developments, LIBOR transition terms and future refinancing or debt-repurchase activity.